NCT07025824View on ClinicalTrials.gov

Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
AML - Acute Myeloid LeukemiaMDS (Myelodysplastic Syndrome)
Interventions
DRUG

Treosulfan (Treo)

10 g/m2 intravenous

DRUG

Melphalan (Mel)

140 mg/m2 intravenous

DRUG

Fludarabine (Flud)

30 mg/m2 intravenous

Trial Locations (4)

Unknown

Medizinische Fakultät der TU Dresden, Medizinische Klinik und Poliklinik I, Dresden

Universitätsmedizin Halle (Saale), Halle

Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel

Universitätsklinikum Münster, Medizinische Klinik A, KMT-Zentrum, Münster

All Listed Sponsors
collaborator

medac GmbH

INDUSTRY

lead

Technische Universität Dresden

OTHER